Infliximab for the Treatment of Refractory Adamantiades-Behçet Disease with Articular, Intestinal, Cerebral and Ocular Involvement

Publisher： Karger

E-ISSN： 1421-9832|220|3|282-286

ISSN： 1018-8665

Source： Dermatology, Vol.220, Iss.3, 2010-01, pp. : 282-286

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Juvenile Adamantiades-Behçet Disease

By  

Dermatology, Vol. 232, Iss. 2, 2016-01 ,pp. : 129-136

Karger

Access to resources Recommend Favorite

Twenty-Eight Cases of Juvenile-Onset Adamantiades-Behçet Disease in Germany

By  

Dermatology, Vol. 199, Iss. 1, 1999-08 ,pp. : 15-19

Karger

Access to resources Recommend Favorite

Mycophenolate Mofetil Is Ineffective in the Treatment of Mucocutaneous Adamantiades-Behçet’s Disease

By  

Dermatology, Vol. 203, Iss. 4, 2001-12 ,pp. : 322-324

Karger

Access to resources Recommend Favorite

Oxidative Stress in Adamantiades-Behçet’s Disease

By  

Dermatology, Vol. 197, Iss. 4, 1998-12 ,pp. : 343-348

Karger

Access to resources Recommend Favorite

Inhibition of Interleukin-1 by Canakinumab as a Successful Mono-Drug Strategy for the Treatment of Refractory Behçet's Disease: A Case Series

By  

Dermatology, Vol. 228, Iss. 3, 2014-03 ,pp. : 211-214

Karger

Access to resources Recommend Favorite